The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease. ADNI researchers collect, validate and utilize data such as MRI and PET images, genetics, cognitive tests, CSF and blood biomarkers as predictors for the disease. Data from the North American ADNI’s study participants, including Alzheimer’s disease patients, mild cognitive impairment subjects and elderly controls, are available from this site.
New CSF Hemoglobin ELISA and PS129 Luminex Assays dataset from Zhang Lab, University of...
Updated MRI micro-hemorrhage assessment results from the Jack Lab at Mayo are available in...